At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 47 enrolled
Drug / intervention
BI 655088 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655088 Administered by Intravenous Infusion in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)
In Brief
A Phase 1 clinical trial evaluating BI 655088 and Placebo for Healthy. Completed, enrolled 47 participants across 1 site.
Detailed Summary
Investigation of safety and tolerability of BI 655088 following intravenous infusion of single rising doses and exploration of the pharmacokinetics and pharmacodynamics of BI 655088 after single dosing
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesBelgium
Collaborators--
Timeline
Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartMar 2016
Primary CompletionFeb 2019
TodayJul 2026
First PostedMar 2, 2016
Enrollment StartMar 16, 2016
Primary CompletionFeb 14, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.3 years ago
Interventions
BI 655088drug
Placebodrug